Crinetics Pharmaceuticals Inc (CRNX) Stock Posted a Gross Margin of -105.50% Over the Past Year: Is This Justifiable?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Crinetics Pharmaceuticals Inc (CRNX) Stock: Unveiling Its Hidden Strengths
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
The CRNX Conundrum: Why Crinetics Pharmaceuticals Inc’s Stock Is Making Headlines Again
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Why Did Crinetics Pharmaceuticals Inc (CRNX) Stock Plunge -6.15% Last Week?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Crinetics Pharmaceuticals Inc (CRNX) Stock: More Robust Than the Numbers Suggest?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Analysts Predict a $68 Target for Crinetics Pharmaceuticals Inc (CRNX) Stock—What Could Drive It There?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
CRNX’s Latest Twist: What’s Fueling the Unexpected Shifts in Crinetics Pharmaceuticals Inc’s Stock Price?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
What is happening with Crinetics Pharmaceuticals Inc (CRNX) Stock?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Crinetics Pharmaceuticals Inc (CRNX) Stock is looking to regain its victory
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
In the long run, Crinetics Pharmaceuticals Inc (CRNX) Stock makes the most sense financially and strategically
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]